NEW YORK - Axsome Therapeutics, Inc. (NASDAQ:AXSM), a company focused on developing therapies for central nervous system disorders, has released the findings of the CRESCENDO survey, which reveal that a significant number of narcolepsy type 1 patients continue to suffer from symptoms despite treatment.
The survey, conducted in partnership with Narcolepsy Network, included 203 adults diagnosed with narcolepsy type 1, all of whom were undergoing FDA-approved treatments.
The survey's results, gathered from October to December 2023, showed that 77% of patients experienced cataplexy, 64% reported excessive daytime sleepiness as measured by the Epworth Sleepiness Scale, and 74% exhibited cognitive impairment according to the British Columbia Cognitive Complaints Inventory. Additionally, 45% and 57% of the patients reported suffering from depression and anxiety, respectively.
Patients in the survey were primarily treated with wake-promoting agents (53%), oxybates (47%), and stimulants (42%). Despite these treatments, the burden of narcolepsy on patients' professional, social, and daily lives remains high, with many reporting embarrassment due to symptoms like falling down and slurred speech.
Dr. Karl Doghramji, a sleep disorder specialist, emphasized the underrecognition of narcolepsy and its impact, highlighting the importance of the CRESCENDO survey in raising awareness and understanding the challenges faced by those living with the disorder.
Axsome Therapeutics plans to present the detailed results of the survey at upcoming scientific meetings. The information for this article is based on a press release statement.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.